Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7215MR)

This product GTTS-WQ7215MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7215MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15487MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ5859MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ12365MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ4598MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ14508MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ7628MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ6660MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ11784MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW